Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting &agr;‐particles or Auger electrons☆

[1]  Pharmacokinetics , 2020, Fundamentals of Analytical Toxicology.

[2]  J. Menéndez,et al.  A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. , 2015, Nuclear medicine and biology.

[3]  M. Minden,et al.  A radiolabeled antibody targeting CD123+ leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML , 2015, Leukemia research reports.

[4]  E. Dadachova,et al.  Abstract 3349: Optimizing radioimmunotherapy techniques for the alpha-emitter 225Actinium , 2015 .

[5]  S. Larson,et al.  Radioimmunotherapy of human tumours , 2015, Nature Reviews Cancer.

[6]  M. Brechbiel,et al.  Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial , 2015, Pharmaceuticals.

[7]  R. Senekowitsch-Schmidtke,et al.  Fractionated intravesical radioimmunotherapy with 213Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma , 2015, Cancer biology & therapy.

[8]  H. Wolterbeek,et al.  A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters? , 2015, Pharmaceuticals.

[9]  E. Estey,et al.  Phase I trial of {alpha}-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML. , 2015 .

[10]  M. Winnik,et al.  Trastuzumab Labeled to High Specific Activity with (111)In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells. , 2015, Molecular pharmaceutics.

[11]  M. Zalutsky,et al.  Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals. , 2015, Nuclear medicine and biology.

[12]  I. Navarro-Teulon,et al.  Introduction to Radiobiology of Targeted Radionuclide Therapy , 2015, Front. Med..

[13]  O. Abdel-Rahman,et al.  Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis. , 2015, Critical reviews in oncology/hematology.

[14]  M. Brechbiel,et al.  Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease , 2015, mAbs.

[15]  M. Minden,et al.  MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells. , 2014, Leukemia research.

[16]  Julien Torgue,et al.  Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab , 2014, The Journal of Nuclear Medicine.

[17]  D. Scheinberg,et al.  Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for α-Particle Radioimmunotherapy of Cancer , 2014, The Journal of Nuclear Medicine.

[18]  D. Ribatti.  From the discovery of monoclonal antibodies to their therapeutic application: an historical reappraisal. , 2014, Immunology letters.

[19]  E. Stang,et al.  The Mysterious Ways of ErbB2/HER2 Trafficking , 2014, Membranes.

[20]  M. Winnik,et al.  Synthesis of polyglutamide-based metal-chelating polymers and their site-specific conjugation to trastuzumab for auger electron radioimmunotherapy. , 2014, Biomacromolecules.

[21]  C. Seidl.  Radioimmunotherapy with α-particle-emitting radionuclides. , 2014, Immunotherapy.

[22]  M. Weinfeld,et al.  The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates. , 2014, Nuclear medicine and biology.

[23]  G. Lockwood,et al.  Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer. , 2014, American journal of nuclear medicine and molecular imaging.

[24]  S. Shen,et al.  Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. , 2014, Cancer biotherapy & radiopharmaceuticals.

[25]  P. Moreau,et al.  213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma , 2013, The Journal of Nuclear Medicine.

[26]  M. Seno,et al.  Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity , 2013, PloS one.

[27]  P. Albertsson,et al.  The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond , 2013, Front. Oncol..

[28]  M. Brechbiel,et al.  Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation. , 2013, Cancer biotherapy & radiopharmaceuticals.

[29]  M. Hedayati,et al.  Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody , 2013, Molecular Cancer Therapeutics.

[30]  M. Brechbiel,et al.  Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies. , 2013, Nuclear medicine and biology.

[31]  R. Salgia,et al.  Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. , 2013, Lung cancer.

[32]  Ø. Bruland,et al.  Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts. , 2013, Current radiopharmaceuticals.

[33]  R. Senekowitsch-Schmidtke,et al.  Alpha-Particle Emitting 213Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation , 2013, PloS one.

[34]  R. Reilly,et al.  Trastuzumab Labeled to High Specific Activity with 111In by Conjugation to G4 PAMAM Dendrimers Derivatized with Multiple DTPA Chelators Exhibits Increased Cytotoxic Potency on HER2-Positive Breast Cancer Cells , 2013, Pharmaceutical Research.

[35]  T. Bäck,et al.  Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb , 2013, EJNMMI Research.

[36]  M. Brechbiel,et al.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. , 2013, Cancer biotherapy & radiopharmaceuticals.

[37]  M. Brechbiel,et al.  Molecular Pathways: Targeted α-Particle Radiation Therapy , 2012, Clinical Cancer Research.

[38]  J. Petersen,et al.  Imaging hypoxia to improve radiotherapy outcome , 2012, Nature Reviews Clinical Oncology.

[39]  Jeffrey V. Leyton,et al.  111In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer , 2012, Breast Cancer Research and Treatment.

[40]  Nathan Schneider,et al.  Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. , 2012, International journal of oncology.

[41]  J. Tabernero,et al.  Application of monoclonal antibodies as cancer therapy in solid tumors. , 2012, Current clinical pharmacology.

[42]  Bryan Hoang,et al.  Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells. , 2012, Biomacromolecules.

[43]  M. Brechbiel,et al.  212Pb-Radioimmunotherapy Induces G2 Cell-Cycle Arrest and Delays DNA Damage Repair in Tumor Xenografts in a Model for Disseminated Intraperitoneal Disease , 2012, Molecular Cancer Therapeutics.

[44]  J. Dick,et al.  Auger Electron Radioimmunotherapeutic Agent Specific for the CD123+/CD131− Phenotype of the Leukemia Stem Cell Population , 2011, The Journal of Nuclear Medicine.

[45]  J. Nesland,et al.  Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab , 2011, EJNMMI research.

[46]  M. Zalutsky,et al.  Astatine-211: production and availability. , 2011, Current radiopharmaceuticals.

[47]  J. Chatal,et al.  The ARRONAX project. , 2011, Current radiopharmaceuticals.

[48]  B. Allen,et al.  Targeted Alpha Therapy Approach to the Management of Pancreatic Cancer , 2011, Cancers.

[49]  J. Humm,et al.  Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody , 2011, Physics in medicine and biology.

[50]  J. Pagel,et al.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. , 2010, Blood.

[51]  Ronald G Blasberg,et al.  Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. , 2010, Cancer research.

[52]  S. Larson,et al.  Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.

[53]  A. Kassis,et al.  Targeted Auger Electron Radiotherapy of Malignancies , 2010 .

[54]  R. Reilly.  The Radiochemistry of Monoclonal Antibodies and Peptides , 2010 .

[55]  R. Reilly,et al.  Antitumor Effects and Normal-Tissue Toxicity of 111In-Nuclear Localization Sequence-Trastuzumab in Athymic Mice Bearing HER-Positive Human Breast Cancer Xenografts , 2010, Journal of Nuclear Medicine.

[56]  F. Paris,et al.  Plasma membrane signaling induced by ionizing radiation. , 2010, Mutation research.

[57]  Jean-Philippe Pignol,et al.  Cellular Dosimetry of 111In Using Monte Carlo N-Particle Computer Code: Comparison with Analytic Methods and Correlation with In Vitro Cytotoxicity , 2010, Journal of Nuclear Medicine.

[58]  R. Reilly,et al.  Methotrexate, Paclitaxel, and Doxorubicin Radiosensitize HER2-Amplified Human Breast Cancer Cells to the Auger Electron–Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab , 2010, Journal of Nuclear Medicine.

[59]  M. Brechbiel,et al.  Improved efficacy of α‐particle–targeted radiation therapy , 2010 .

[60]  M. Schwaiger,et al.  Intravesical α-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice , 2009, Journal of Nuclear Medicine.

[61]  L. Jacobsson,et al.  Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study , 2009, Journal of Nuclear Medicine.

[62]  R. Reilly,et al.  Computational analysis of the number, area and density of γ-H2AX foci in breast cancer cells exposed to 111In-DTPA-hEGF or γ-rays using Image-J software , 2009, International journal of radiation biology.

[63]  P. Russell,et al.  Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206 , 2008, Cancer biology & therapy.

[64]  M. Minden,et al.  Drug-Resistant AML Cells and Primary AML Specimens Are Killed by 111In-Anti-CD33 Monoclonal Antibodies Modified with Nuclear Localizing Peptide Sequences , 2008, Journal of Nuclear Medicine.

[65]  Amin I Kassis,et al.  Therapeutic radionuclides: biophysical and radiobiologic principles. , 2008, Seminars in nuclear medicine.

[66]  R. Reilly,et al.  Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron–Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate , 2008, Journal of Nuclear Medicine.

[67]  M. Brechbiel,et al.  Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal Disease , 2008, Clinical Cancer Research.

[68]  Manuel Bardiès,et al.  Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons , 2008, Radiation research.

[69]  Katherine A Vallis,et al.  Relationship Between Induction of Phosphorylated H2AX and Survival in Breast Cancer Cells Exposed to 111In-DTPA-hEGF , 2008, Journal of Nuclear Medicine.

[70]  M. Boyd,et al.  Radiation quality‐dependent bystander effects elicited by targeted radionuclides , 2008, The Journal of pharmacy and pharmacology.

[71]  W. Mcbride,et al.  Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. , 2008, Cancer research.

[72]  M. Ychou,et al.  Adjuvant Radioimmunotherapy Trial with Iodine-131–Labeled Anti–Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab′)2 after Resection of Liver Metastases from Colorectal Cancer , 2008, Clinical Cancer Research.

[73]  M. Piccart.  Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer. , 2008, Clinical breast cancer.

[74]  R. Reilly,et al.  Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. , 2008, Cancer biotherapy & radiopharmaceuticals.

[75]  D. Goldenberg,et al.  Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[76]  R. Coleman,et al.  Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 , 2007, Journal of Nuclear Medicine.

[77]  R. Reilly,et al.  Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF. , 2007, Nuclear medicine and biology.

[78]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[79]  L. Jacobsson,et al.  Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. , 2007, International journal of radiation oncology, biology, physics.

[80]  D. Goldenberg,et al.  CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms , 2007, Clinical Cancer Research.

[81]  R. Reilly,et al.  111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer , 2007, Journal of Nuclear Medicine.

[82]  M. Schwaiger,et al.  213Bi‐radioimmunotherapy defeats early‐stage disseminated gastric cancer in nude mice , 2007, Cancer science.

[83]  M. Brechbiel,et al.  Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease , 2007, Clinical Cancer Research.

[84]  K. Schwarz,et al.  Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. , 2007, Cancer research.

[85]  L. Jacobsson,et al.  Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2. , 2006, International journal of radiation oncology, biology, physics.

[86]  L. Jacobsson,et al.  Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. , 2006, Nuclear medicine and biology.

[87]  L. Jacobsson,et al.  Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[88]  Ketai Wang,et al.  Inhibitory and Stimulatory Bystander Effects are Differentially Induced by Iodine-125 and Iodine-123 , 2006, Radiation research.

[89]  Michael R Zalutsky,et al.  Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[90]  R. Cameron,et al.  Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[91]  Paul Chen,et al.  Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[92]  D. Hicklin,et al.  Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts , 2006, Clinical Cancer Research.

[93]  L. Jacobsson,et al.  Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[94]  M. Brechbiel,et al.  Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. , 2005, Cancer biotherapy & radiopharmaceuticals.

[95]  D. Scheinberg,et al.  Efforts to control the errant products of a targeted in vivo generator. , 2005, Cancer research.

[96]  R. Michel,et al.  In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2 , 2005, Molecular Cancer Therapeutics.

[97]  E. Estey,et al.  Acute Myelogenous Leukemia , 2005 .

[98]  D. Goldenberg,et al.  Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  M. Zalutsky,et al.  Radioimmunotherapy with alpha-particle emitting radionuclides. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[100]  D. Scheinberg,et al.  Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of α-Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2 , 2004, Clinical Cancer Research.

[101]  R. Michel,et al.  In vitro Toxicity of A-431 Carcinoma Cells with Antibodies to Epidermal Growth Factor Receptor and Epithelial Glycoprotein-1 Conjugated to Radionuclides Emitting Low-Energy Electrons , 2004, Clinical Cancer Research.

[102]  L. Chappell,et al.  Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. , 2004, Cancer biotherapy & radiopharmaceuticals.

[103]  Luther W Brady,et al.  Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. , 2004, International journal of radiation oncology, biology, physics.

[104]  R. Cameron,et al.  Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[105]  D. Scheinberg,et al.  Targeted actinium-225 in vivo generators for therapy of ovarian cancer. , 2003, Cancer research.

[106]  M. Brechbiel,et al.  A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[107]  S. Adelstein,et al.  Bystander effect produced by radiolabeled tumor cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[108]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[109]  R. Michel,et al.  Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[110]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  G. Denardo,et al.  Combined modality radioimmunotherapy , 2002, Cancer.

[112]  D. Scheinberg,et al.  Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.

[113]  J. Vose,et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[115]  J. Humm,et al.  Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[116]  P. Dennis,et al.  Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. , 2001, Cancer research.

[117]  D. Goldenberg,et al.  Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[118]  S. Mirzadeh,et al.  In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. , 2001, Cancer biotherapy & radiopharmaceuticals.

[119]  M. Brechbiel,et al.  Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[120]  D. Howard,et al.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.

[121]  M. Béhé,et al.  Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies , 2000, European Journal of Nuclear Medicine.

[122]  J. Gariépy,et al.  111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[123]  A. Burroughs,et al.  Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours , 2000, Nuclear medicine communications.

[124]  C. S. Hassfjell.  Survival of human lung epithelial cells following in vitro α-particle irradiation with absolute determination of the number of alpha-particle traversals of individual cells , 2000, International journal of radiation biology.

[125]  S. Adelstein,et al.  Strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125: direct compared to indirect effects. , 1999, Radiation research.

[126]  G. Griffiths,et al.  Cytotoxicity with Auger electron‐emitting radionuclides delivered by antibodies , 1999, International journal of cancer.

[127]  S. Adelstein,et al.  Comparison of strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125. , 1999, Radiation research.

[128]  A. Haimovitz-Friedman.  Radiation-induced signal transduction and stress response. , 1998, Radiation research.

[129]  J. Humm,et al.  Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.

[130]  D. Goldenberg,et al.  Therapeutic efficacy and dose‐limiting toxicity of auger‐electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of 125I‐ vs. 131I‐labeled CO17‐1A in a human colorectal cancer model , 1998, International journal of cancer.

[131]  J. Rossi,et al.  Phase‐I/II radio‐immunotherapy study with iodine‐131‐labeled anti‐CEA monoclonal antibody F6 F(ab′)2 in patients with non‐resectable liver metastases from colorectal cancer , 1998, International journal of cancer.

[132]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[133]  D. Bigner,et al.  Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. , 1997, Nuclear medicine and biology.

[134]  R. Moritz,et al.  The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[135]  G. Griffiths,et al.  Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. , 1996, The Biochemical journal.

[136]  S. Larson,et al.  Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. , 1995, Cancer research.

[137]  H. Earp,et al.  Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research , 1995, Breast Cancer Research and Treatment.

[138]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[139]  S. Gallinger,et al.  Problems of Delivery of Monoclonal Antibodies , 1995, Clinical pharmacokinetics.

[140]  A. Haimovitz-Friedman,et al.  The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation. , 1994, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[141]  M. Hung,et al.  Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. , 1994, Biochemical and biophysical research communications.

[142]  M. Nikolic,et al.  Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. , 1994, British Journal of Cancer.

[143]  T. Waldmann,et al.  Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac , 1994 .

[144]  A. Scott,et al.  Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  T. Walz,et al.  Transforming growth factor alpha in human bone marrow Demonstration of TGF-alpha in erythroblasts and eosinophilic precursor cells and of epidermal growth factor receptors in blast-like cells of myelomonocytic origin , 1994 .

[146]  K. Shinohara,et al.  Cell killing induced by decay of 125I during the cell cycle: comparison of 125I-antipyrine with 125I-bovine serum albumin. , 1993, Radiation research.

[147]  M. Brechbiel,et al.  Effective α-Particle-mediated Radioimmunotherapy of Murine Leukemia , 1992 .

[148]  S. Larson.  Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. , 1991, Journal of the National Cancer Institute.

[149]  M. Welch,et al.  Radiotoxicity of 5-[123I]iodo-2'-deoxyuridine in V79 cells: a comparison with 5-[125I]iodo-2'-deoxyuridine. , 1989, Radiation research.

[150]  C. Cordon-Cardo,et al.  Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. , 1989, Leukemia.

[151]  F. Buchegger,et al.  Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments. , 1989, The Journal of clinical investigation.

[152]  D. Charlton,et al.  A Monte Carlo simulation of Auger cascades. , 1987, Radiation research.

[153]  S. Adelstein,et al.  Radiotoxicity of 125I in mammalian cells. , 1987, Radiation research.

[154]  S. Adelstein,et al.  Thallium-201: an experimental and a theoretical radiobiological approach to dosimetry. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[155]  K. Hofer,et al.  Radiotoxicity of Intracellular 67Ga, 125I and 3H , 1975 .

[156]  J. Pagel,et al.  TRANSPLANTATION Anti-CD45 radioimmunotherapy using 211 At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model , 2013 .

[157]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[158]  N. Jonjić,et al.  Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis , 2010, Modern Pathology.

[159]  M. Brechbiel,et al.  Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. , 2010, Cancer.

[160]  F. E. Bertrand,et al.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy , 2009, Leukemia.

[161]  Ravy K. Vajravelu,et al.  Experimental Therapeutics , Molecular Targets , and Chemical Biology Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225 Ac : Comparing Efficacy with 213 Bi and 90 Y , 2009 .

[162]  E. Dadachova,et al.  The Na/I symporter (NIS): imaging and therapeutic applications. , 2004, Seminars in nuclear medicine.

[163]  D. Scheinberg,et al.  Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[164]  J. Burke,et al.  Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias , 2003, Bone Marrow Transplantation.

[165]  J. Humm,et al.  Targeted alpha particle immunotherapy for myeloid leukemia. , 2002, Blood.

[166]  J. Baselga,et al.  Mechanism of action of anti-HER2 monoclonal antibodies. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[167]  D. Goldenberg,et al.  Single-cell cytotoxicity with radiolabeled antibodies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[168]  L. Jacobsson,et al.  Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. , 2001, Anticancer research.

[169]  J. Baselga.  Clinical trials of Herceptin(trastuzumab). , 2001, European journal of cancer.

[170]  L. Jacobsson,et al.  The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study. , 2000, Acta oncologica.

[171]  T. Back,et al.  Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18. , 2000, Anticancer research.

[172]  D. Scheinberg,et al.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[173]  J. Gamble,et al.  Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist. , 1996, Blood.

[174]  M. Brechbiel,et al.  Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. , 1994, Cancer research.

[175]  N. Lemoine,et al.  The type 1 (EGFR-related) family of growth factor receptors and their ligands. , 1992, Progress in growth factor research.

[176]  M. Schrappe,et al.  Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. , 1992, Cancer research.

[177]  M. Brechbiel,et al.  Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. , 1992, Cancer research.

[178]  S. Adelstein,et al.  Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. , 1987, Radiation research.

[179]  M. Zalutsky,et al.  A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. , 1987, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[180]  T. Waldmann,et al.  Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[181]  R. Warters,et al.  Radionuclide toxicity in cultured mammalian cells: elucidation of the primary site of radiation damage. , 1978, Current topics in radiation research quarterly.